Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China
HANGZHOU, China and SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of patient dosing in Phase 3 clinical trials of ecnoglutide (XW003) in adult patients with type 2 diabetes in China. Ecnoglutide is a novel, long-acting glucagon-like...
Novotech Awarded by Frost & Sullivan for Global Biotech Clinical Trials Excellence in APAC
With a proven biotech market leadership position, Novotech's compelling value proposition drives its sustained success in delivering biotech clinical trials. SAN ANTONIO, Jan. 31, 2023 /PRNewswire/ -- Frost & Sullivan recently analyzed the Asia-Pacific contract research organization industry and, based on its findings, recognizes Novotech with the 2022 Asia-Pacific Contract Research Organization Company...
Look Back Upon the Development of VOOPOO DRAG MODs, Witness the Legend of the E-cigarette Industry
SHENZHEN, China, Jan. 30, 2023 /PRNewswire/ -- At the end of 2022, the vape giant VOOPOO released the brand new product DRAG 4 from its famous series DRAG, and let global users once again see the legendary power of the e-cigarette industry. We are now looking back the development of VOOPOO DRAG and learning its legend story! From 2017,...
Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China
BEIJING, Jan. 30, 2023 /PRNewswire/ -- Help Therapeutics Co., Ltd. (hereinafter Help Therapeutics) has revealed that the China Center for Drug Evaluation (CDE) has approved the investigational new drug (IND) application of HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in patients with worsening ischemic heart failure. China CDE has approved Help Therapeutics to study the safety and efficacy...
Health in Tech to Attend Health Care Administration Association (HCAA) Executive Forum 2023 as Corporate Sponsor
HCAA's Executive Forum 2023 is scheduled for February 20-22, 2023, at the Bellagio in Las Vegas. Be sure to stop by booth NL #9 to meet Health in Tech leadership. STUART, Fla., Jan. 30, 2023 /PRNewswire/ -- Health in Tech ("HIT", or "the Company"), an industry-leading Insurtech company that delivers disruptive innovation...
Syntach AB announces €17.5M in Blended Funding, Names Patrick NJ Schnegelsberg as New CEO, and Appoints Cansel Isikli as VP of RA/Q
LUND, Sweden, Jan. 30, 2023 /PRNewswire/ - Swedish medtech startup Syntach AB has been awarded up to €15 million in equity financing by European Innovation Council (EIC) for the development of the Syntach Cardiac Support System, a breakthrough device for patients with heart failure. This approval follows the award of a €2.5...
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+,...
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations,...
Duoning Headquarters in Fengxian Biotechnology Park with Centers for R&D and Technology Applications
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Shanghai Duoning Biotechnology Co., Ltd. ("Duoning") announced that the company signed an Agreement on the Transfer of the Right to Use State-owned Construction Land with the Bureau of Planning and Natural Resources of Fengxian District, Shanghai and officially settled its global headquarters in the Biotechnology Park of Shanghai Fengxian Economic Development Zone. And Duoning will...
Chula Medicine Reveals Detection of Latent Dementia
Thai Red Cross Emerging Infectious Diseases Health Science Center, Faculty of Medicine, Chulalongkorn University has researched a blood test for markers of Alzheimer's that can give a 10-year warning, so people can be prepared to slow down the development of dementia in old age. BANGKOK, Jan. 30, 2023 /PRNewswire/ -- Poosanu Thanapornsangsuth, M.D., lecturer of Neurology, the Department of Internal...
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor Pimicotinib（ABSK021）has been granted the breakthrough therapy designation from FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients that are not amenable to surgery. This breakthrough therapy designation approval is based on results from the phase Ib clinical trial...
